EFM
MDGL icon

E Fund Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

E Fund Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469K Sell
873
-474
-35% -$243K 0.01% 286
2026
Q1 		$705K Buy
+1,347
New +$644K 0.02% 219
2025
Q2 		$829K Sell
2,739
-56
-2% -$16.7K 0.04% 185
2025
Q1 		$926K Buy
2,795
+440
+19% +$145K 0.04% 177
2024
Q4 		$727K Sell
2,355
-508
-18% -$143K 0.04% 182
2024
Q3 		$608K Buy
2,863
+651
+29% +$167K 0.03% 180
2024
Q2 		$620K Buy
2,212
+514
+30% +$122K 0.03% 158
2024
Q1 		$453K Sell
1,698
-608
-26% -$143K 0.03% 171
2023
Q4 		$534K Sell
2,306
-21
-0.9% -$3.67K 0.03% 148
2023
Q3 		$340K Buy
2,327
+644
+38% +$121K 0.03% 196
2023
Q2 		$389K Buy
1,683
+84
+5% +$22.8K 0.03% 180
2023
Q1 		$387K Sell
1,599
-3,933
-71% -$1.07M 0.03% 177
2022
Q4 		$1.61M Buy
5,532
+994
+22% +$97.2K 0.13% 66
2022
Q3 		$295K Buy
4,538
+968
+27% +$67.3K 0.03% 241
2022
Q2 		$256K Buy
3,570
+1,248
+54% +$91.7K 0.02% 259
2022
Q1 		$228K Buy
+2,322
New +$196K 0.01% 271

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E Fund Management's MDGL Position: Q2 2026 in Review

E Fund Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 35% in Q2 2026, selling an estimated $243K and leaving 873 shares worth $469K. The position accounts for 0.01% of the portfolio, ranked #286.

E Fund Management first reported a position in MDGL in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.61M in Q4 2022. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • E Fund Management held 873 shares of Madrigal Pharmaceuticals worth $469K as of Q2 2026.
  • E Fund Management sold 474 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $243K.
  • Madrigal Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2026, its #286 holding.
  • E Fund Management first reported a position in Madrigal Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's Madrigal Pharmaceuticals position peaked at $1.61M in Q4 2022.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.